FindTrial
Sign In

Targeting Lupus in old age and children using omics approach and validating the same by gene editing for patient personalized medicine

Targeting SLE heterogeneity in geriatric & childhood lupus using single-cell transcriptomics & validation using a CRISPR-based gene editing system for patient-specific precision medicine

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/08/057076
Enrollment
60
Registered
2023-08-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M048- Other autoinflammatory syndromes

Interventions

None listed

Sponsors

DEPARTMENT OF HEALTH RESEARCH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Pediatric group from 0-12 Geriatric group above 50 years

Exclusion criteria

Exclusion criteria: 1.Patient with other autoimmune disease 2. Patient with comorbidities 3. Patient with malignancy

Design outcomes

Primary

MeasureTime frame
We will characterize immune cell heterogeneity and their differential expression in juvenile and age onset SLE at flare and remission. Timepoint: 24 months—

Secondary

MeasureTime frame
We will understand cell type specific expression difference in elderly onset & childhood lupus.Early diagnosis & understanding SLE pathogenesis by developing appropriate transcriptomic signature. scRNA technology is expected to reveal patient-based precision molecular therapy. CRISPR- Cas 9 gene editing tool in immune cell will further unraveling novel immune pathways & developing deep insight therapies for SLE with no curative therapeutic option. Timepoint: 24MONTHS—

Countries

India

Contacts

Public ContactAbhibroto Karmakar

Kasturba Medical College ,Manipal

abhibroto.karmakar@learner.manipal.edu9051469974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026